Variant · Snv
MAP2K1 C121S
CI-VAR-00000266Explore in graph →NP_002746.1:p.Cys121SerNM_002755.3:c.362G>CClinVar 375980 CIViC 627
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25899310
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Langerhans Cell Histiocytosis1 | ||||||||
| MAP2K1 C121S AND MAP2K1 G128D | Trametinib | Predictive | D | Supports Resistance | 3 | submitted | EID6385The C121S/G128D and 56_61QKQKVG>R variants were resistant to the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib in vitro. All three variant proteins constitutively phosphorylated E… (full text at CIViC) PMID 25899310 · Nelson et al., 2015 · Open in CIViC | civic |
| Malignant Colorectal Neoplasm1 | ||||||||
| BRAF V600E AND MAP2K1 C121S | Cetuximab + Irinotecan + VemurafenibCombination | Predictive | C | Supports Resistance | 2 | submitted | EID1903Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. Three patient… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available